At the news
? NEUTRALIMPACT 1/10 COURT-RULING filed Sep 7, 2026 at 20:00 ET
Novo Nordisk and defendant Aios Inc. (d/b/a Fella Health) entered a stipulated ESI discovery order in the Northern District of California. This is a routine procedural order governing the format, search, and production of electronically stored information in the patent litigation. It has no material financial or operational impact on Novo Nordisk's business or stock.
- The order is a stipulated ESI discovery protocol, not a ruling on the merits.
- The case is Novo Nordisk A/S et al v. Aios Inc. et al (4:25-cv-06560-YGR).
- The order was entered on September 8, 2026, by Magistrate Judge Thomas S. Hixson.
- No damages, injunctions, or liability determinations were made.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access